Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 11, 83

Banha-sasim-tang as an Herbal Formula for the Treatment of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled, Two-Center Trial

Affiliations
Randomized Controlled Trial

Banha-sasim-tang as an Herbal Formula for the Treatment of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled, Two-Center Trial

Jae-Woo Park et al. Trials.

Abstract

Background: Functional dyspepsia (FD) is characterized by a high prevalence rate and no standard conventional treatments. Alternative therapies, such as herbal formulas, are widely used to treat FD. However, there are inadequate evidences regarding the safety and efficacy of these formulas. Moreover, the mechanisms by which herbal formulas act in the gastrointestinal tract are controversial. In traditional Korean medicine, Banha-sasim-tang has long been one of the most frequently prescribed herbal formulas for treating dyspepsia. The current study is designed to evaluate the efficacy and safety of Banha-sasim-tang for FD patients and to examine whether there will be a significant correlation between cutaneous electrogastrography recordings and dyspeptic symptoms in FD patients, and between changes in gastric myoelectrical activity and improvement in dyspeptic symptoms during Banha-sasim-tang administration.

Methods: This randomized, double-blind, placebo-controlled trial will be performed at two centers and will include a Banha-sasim-tang group and placebo group. Each group will consist of 50 FD patients. Six weeks of administration of Banha-sasim-tang or placebo will be conducted. During the subsequent 2 months, follow-up observations of primary and secondary outcomes will be performed. The primary outcomes are differences as measured on the gastrointestinal symptom scale, and the secondary outcomes are differences as measured on the visual analogue scale for dyspepsia and on the questionnaire for FD-related quality of life. All outcomes will be measured at baseline, at 2, 4, and 6 weeks of treatment, and at the 1 and 2 month follow-up. Cutaneous electrogastrography will be performed and assessed at baseline and at 6 weeks.

Discussion: This trial will provide evidence of the safety and efficacy of Banha-sasim-tang for the treatment for FD. Furthermore, based on the assessment of the relationship between cutaneous electrogastrography recordings and dyspeptic symptoms in this trial, the possibility of clinical applications of cutaneous electrogastrography in the treatment of FD will be elucidated.

Trial registration: Current Controlled Trials (ISRCTN 51910678); Clinical Trials.gov Identifier: NCT00987805.

Figures

Figure 1
Figure 1
Flow chart of the trial.

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles

References

    1. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion. 2004;69:45–52. doi: 10.1159/000076546. - DOI - PubMed
    1. von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007;102:1268–1275. doi: 10.1111/j.1572-0241.2006.01183.x. - DOI - PubMed
    1. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, Richter JE, Koch GG. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569–1580. doi: 10.1007/BF01303162. - DOI - PubMed
    1. Lee JS. The guideline for diagnosis of functional dyspepsia. Kor J Neuroenterol Motil. 2005;11(3):18–24.
    1. Sha W, Pasricha PJ, Chen JD. Correlations among electrogastrogram, gastric dysmotility, and duodenal dysmotility in patients with functional dyspepsia. J Clin Gastroenterol. 2009;43(8):716–722. doi: 10.1097/MCG.0b013e31818b8ed9. - DOI - PubMed

Publication types

Associated data

Feedback